Clinical Trials Browser

Phase 1/2 × Lymphoma, T-Cell × tenalisib × Clear all

NCT03770000 2022-10-28

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Phase 1/2 Completed

33 enrolled 13 charts

Lymphoma, T-Cell